Adjuvant RT

OTHER2 trials

Sponsors

Tata Memorial Centre, University of Chicago

Conditions

Bladder CancerHNSCCHPV-Related Squamous Cell CarcinomaUrothelial Carcinoma Bladder

Phase 2

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

CompletedNCT03107182

University of ChicagoHNSCC, HPV-Related Squamous Cell Carcinoma

Start: 2017-06-27End: 2024-09-06Updated: 2025-05-06

Phase 3

Bladder Cancer Adjuvant Radiotherapy Trial

Active, not recruitingNCT02951325

Tata Memorial CentreBladder Cancer, Urothelial Carcinoma Bladder

Start: 2016-06-02End: 2030-04-13Target: 153Updated: 2025-02-13

Related Papers

Circulating tumor HPV-DNA dynamics and neoadjuvant chemotherapy with or without nivolumab in viral-mediated oropharyngeal cancer.

Journal of Clinical Oncology2025-05-281 citations

Functional and survival outcomes in HPV positive oropharyngeal squamous cell cancer treated with response-adaptive de-escalation: A pooled analysis.

Journal of Clinical Oncology2025-05-28

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV<sup>+</sup> Oropharyngeal Cancer

JAMA Oncology2024-06-0638 citations

Nivolumab-based induction chemoimmunotherapy and PD-L1 expression in locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma.

Journal of Clinical Oncology2022-06-012 citations

Swallowing and quality-of-life outcomes of response adaptive de-escalated therapy following nivolumab-based induction for HPV+ oropharyngeal cancer.

Journal of Clinical Oncology2022-06-011 citations

Bone Marrow Suppression during Postoperative Radiation for Bladder Cancer and Comparative Benefit of Proton Therapy-Phase 2 Trial Secondary Analysis.

2021-07-066 citations

Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

Journal of Clinical Oncology2021-05-2029 citations

Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.

Journal of Clinical Oncology2021-05-206 citations